Inclusion Criteria:

- Diagnosis of NF2 by National Institutes of Health (NIH) criteria

- Age ≥ 16 years

- Progressive VS growth during the previous 12 months.

- WHO performance status > or = 2

- Adequate bone marrow, liver and renal function.

- For women of childbearing potential, no pregnancy or breast-feeding

- Willingness and ability to comply with scheduled visits, drug administration plan,
laboratory tests, other study procedures, and study restrictions.

- Willingness to provide informed consent

Exclusion Criteria:

- Inability to tolerate periodic MRI scans or gadolinium contrast.

- Inability to tolerate periodic audiologic testing or to understand a language with
established scoring for word recognition testing.

- Inability to adequately perform volumetric measurement of at least 1 target
lesionNote: Patients with cochlear or auditory brainstem implants may participate if
a target lesion can be accurately assessed.

- Radiation therapy for the target lesion in the 60 months preceding inclusion in the
study.

- Patients currently receiving anticancer therapies or who have received anticancer
therapies within 4 weeks of the start of study drug.

- Immunization with attenuated live vaccines within one week of study entry or during
study period.

- Presence of a fungal infection requiring systemic antifungal treatment at enrollment

- Other malignancies within the past 3 years except for adequately treated carcinoma of
the cervix or basal or squamous cell carcinomas of the skin.

- Patients who have any severe and/or uncontrolled medical conditions.

- Patients with a known hypersensitivity to everolimus or other types of rapamycin or
to its excipients.

- Patients unwilling to or unable to comply with the protocol